for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

UCB SA

UCB.BR

Latest Trade

70.76EUR

Change

0.26(+0.37%)

Volume

715,047

Today's Range

69.76

 - 

71.68

52 Week Range

62.26

 - 

80.06

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Latest Developments

Amgen Says Evenity® (Romosozumab) Receives Positive CHMP Opinion For Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

Oct 18 (Reuters) - Amgen Inc <AMGN.O>::EVENITY® (ROMOSOZUMAB) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF SEVERE OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK OF FRACTURE.

Ra Pharmaceuticals - If Deal Is Terminated, Co May Be Required To Pay UCB S.A. A Termination Fee Of $75 Mln In Cash

Oct 10 (Reuters) - Ra Pharmaceuticals Inc <RARX.O>::RA PHARMACEUTICALS - IF DEAL IS TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO MAY BE REQUIRED TO PAY UCB S.A. A TERMINATION FEE OF $75 MILLION IN CASH.

UCB Agrees To Acquire Ra Pharmaceuticals For 2.1 Billion Dollars

Oct 10 (Reuters) - UCB SA <UCB.BR>::UCB AGREES TO ACQUIRE RA PHARMACEUTICALS.JOINING FORCES TO IMPROVE TREATMENT OPTIONS FOR PEOPLE LIVING WITH MYASTHENIA GRAVIS AND OTHER RARE DISEASES.ACQUISITION WILL NOT IMPACT UCB'S 2019 FINANCIAL GUIDANCE.ACQUISITION WILL ENABLE ACCELERATED TOP AND BOTTOM LINE GROWTH FROM 2024 ONWARDS.TOTAL TRANSACTION VALUE OF AROUND US$ 2.1 BILLION / € 2.0 BILLION (NET OF RA PHARMA CASH) BASED ON US$ 48 IN CASH PER RA PHARMACEUTICALS SHARE (APPROXIMATELY US$ 2.5BN / € 2.2BN).DEAL WOULD BE DILUTIVE TO UCB'S MID-TERM EARNINGS LEVEL.DEAL WOULD MOVE MID-TERM TARGET OF UCB REACHING A REBITDA RATIO (TO REVENUE) OF 31% TO 2022 FROM 2021 AS PREVIOUSLY GUIDED.UCB AND RA PHARMA EXPECT TO COMPLETE TRANSACTION BY END OF Q1 2020.

UCB H1 Revenue Up At 2.3 Billion Euros

July 25 (Reuters) - UCB SA <UCB.BR>::H1 VIMPAT NET SALES EUR 622 MILLION VERSUS EUR 522 MILLION YEAR AGO.UCB HALF YEAR REPORT 2019: UCB'S STRONG PERFORMANCE ENABLES CONTINUED INVESTMENT INTO FUTURE GROWTH DRIVERS.H1 REVENUE REACHED EUR 2.3 BILLION (+2%, +4% CER(1)).H1 CIMZIA NET SALES EUR 782 MILLION VERSUS EUR 679 MILLION YEAR AGO.H1 UNDERLYING PROFITABILITY (REBITDA(3)) WAS EUR 724 MILLION (-9%, -1% CER) OR A RATIO OF 31%.FINANCIAL OUTLOOK FOR 2019 CONFIRMED.H1 KEPPRA NET SALE EUR 371 MILLION VERSUS EUR 392 MILLION YEAR AGO.H1 BRIVIACT NET SALES EUR 103 MILLION VERSUS EUR 60 MILLION YEAR AGO.H1 NEUPRO NET SALES EUR 158 MILLION VERSUS EUR 148 MILLION YEAR AGO.CFO TRANSITION IN 2020.CHIEF FINANCIAL OFFICER, DETLEF THIELGEN, WILL BE TRANSITIONING OUT WITHIN A YEAR FROM NOW. A SEARCH FOR A SUCCESSOR HAS JUST BEGUN..H1 VIMPAT NET SALES EUR 622 MILLION VERSUS EUR 522 MILLION YEAR AGO.

UCB H1 Net Sales Increased To 2.2 Billion Euros

July 25 (Reuters) - UCB SA <UCB.BR>::UCB HALF YEAR REPORT 2019: UCB'S STRONG PERFORMANCE ENABLES CONTINUED INVESTMENT INTO FUTURE GROWTH DRIVERS.H1 REVENUE REACHED EUR 2.3 BILLION (+2%, +4% CER(1)).H1 CIMZIA NET SALES EUR 782 MILLION VERSUS EUR 679 MILLION YEAR AGO.H1 UNDERLYING PROFITABILITY (REBITDA(3)) WAS EUR 724 MILLION (-9%, -1% CER) OR A RATIO OF 31%.H1 VIMPAT NET SALES EUR 371 MILLION VERSUS EUR 522 MILLION YEAR AGO.FINANCIAL OUTLOOK FOR 2019 CONFIRMED.H1 VIMPAT NET SALES EUR 622 MILLION VERSUS EUR 522 MILLION YEAR AGO.H1 KEPPRA NET SALE EUR 371 MILLION VERSUS EUR 392 MILLION YEAR AGO.H1 BRIVIACT NET SALES EUR 103 MILLION VERSUS EUR 60 MILLION YEAR AGO.H1 NEUPRO NET SALES EUR 158 MILLION VERSUS EUR 148 MILLION YEAR AGO.H1 REBITDA EUR 724 MILLION VERSUS EUR 794 MILLION YEAR AGO.OUTLOOK 2019 CONFIRMED.CFO TRANSITION IN 2020.CHIEF FINANCIAL OFFICER, DETLEF THIELGEN, WILL BE TRANSITIONING OUT WITHIN A YEAR FROM NOW. A SEARCH FOR A SUCCESSOR HAS JUST BEGUN..

UCB Announces Approval Of Cimzia In China

July 22 (Reuters) - Ucb SA <UCB.BR>::UCB ANNOUNCES APPROVAL OF CIMZIA IN CHINA.RESULTS OF THE RAPID-C AND RAPID-C OLE TRIALS DEMONSTRATE THE POTENTIAL VALUE OF CIMZIA FOR CHINESE PATIENTS.

UCB And Amgen Provide Regulatory Update On Status Of EVENITY in EU

June 28 (Reuters) - UCB SA <UCB.BR>::UCB AND AMGEN PROVIDE REGULATORY UPDATE ON STATUS OF EVENITY® (ROMOSOZUMAB) IN THE EU.COMPANIES INTEND TO SUBMIT A WRITTEN NOTICE FOR A RE-EXAMINATION BY THE CHMP.UCB AND AMGEN WERE INFORMED THAT CHMP OF EMA ADOPTED NEGATIVE OPINION ON MARKETING AUTHORISATION APPLICATION FOR EVENITY (ROMOSOZUMAB).

Amgen Says CHMP OF EMA Adopted Negative Opinion On MAA For Evenity

June 28 (Reuters) - Amgen Inc <AMGN.O>::AMGEN AND UCB PROVIDE REGULATORY UPDATE ON STATUS OF EVENITY™ (ROMOSOZUMAB) IN THE EU.AMGEN - CHMP OF EMA ADOPTED NEGATIVE OPINION ON MARKETING AUTHORIZATION APPLICATION FOR EVENITY (ROMOSOZUMAB) FOR TREATMENT OF SEVERE OSTEOPOROSIS.AMGEN INC - COMPANIES INTEND TO SUBMIT A WRITTEN NOTICE FOR A RE-EXAMINATION BY CHMP.AMGEN INC - "DISAPPOINTED" WITH CHMP OPINION AND BELIEVE THAT BODY OF EVIDENCE SUBMITTED SUPPORTS A "POSITIVE BENEFIT".AMGEN INC - CONTINUE TO BELIEVE THAT EVENITY HAS A POSITIVE BENEFIT OF RISK PROFILE.AMGEN INC - RE-EXAMINATION PROCESS GIVES COS OPPORTUNITY TO CLARIFY POSITION ON SUBMITTED DATA.

UCB Initiates Phase 1B US-Based Multicenter Clinical Trial In Parkinson’S Disease Patients

May 28 (Reuters) - UCB SA <UCB.BR>::UCB INITIATES PHASE 1B US-BASED MULTICENTER CLINICAL TRIAL IN PARKINSON’S DISEASE PATIENTS WITH UCB0599, A COMPOUND ARISING FROM THE NEUROPORE-UCB COLLABORATION.SAYS NEUROPORE WILL RECEIVE A $5 MILLION (USD) AWARD AS A RESULT OF ACHIEVING THIS MILESTONE..

UCB Nayzilam Nasal Spray Approved By FDA

May 20 (Reuters) - UCB SA <UCB.BR>::UCB ANNOUNCES NAYZILAM® (MIDAZOLAM) NASAL SPRAY NOW APPROVED BY FDA TO TREAT INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PEOPLE LIVING WITH EPILEPSY IN THE U.S..NAYZILAM IS THE FIRST NEW MEDICATION APPROVED TO TREAT SEIZURE CLUSTERS IN MORE THAN 20 YEARS IN THE U.S.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up